Matches in DBpedia 2014 for { <http://dbpedia.org/resource/GenSpera> ?p ?o. }
Showing items 1 to 29 of
29
with 100 items per page.
- GenSpera abstract "GenSpera, Inc. (OTC:BB GNSZ) is a development-stage oncology company based in San Antonio, Texas. The company is focused on therapeutics that deliver a cancer-destroying drug directly to the tumor or its supporting environment, the tumor vasculature.The company's prodrug technology renders the drug inactive until it encounters the programmed target, thereby delivering the cytotoxin directly to the cancer or the vessels that support it, while potentially avoiding the side effects associated with current chemotherapies. A prodrug is an inactive precursor of a drug that is converted into its active form at a targeted site.GenSpera's first drug, G-202, targets the enzyme PSMA, found on the walls of blood vessels that feed most cancerous tumors, destroying the tumor blood supply. In contrast with anti-angiogenesis treatments, G-202 destroys existing as well as new cancer blood vessels.The active ingredient in G-202 is a chemotherapeutic agent derived from thapsigargin, a plant-based cytotoxin that kills by disrupting the calcium balance in cancer cells. GenSpera's prodrug delivery system keeps the thapsigargin inactive in the body until it finds cells that it has been programmed to seek. Once those cells in the body are found, the prodrug releases its active ingredient and destroys all of the targeted cells.The National Cancer Institute had previously demonstrated that thaspigargin was ten-to-a-hundredfold more potent than traditional chemotherapeutic agents in killing all types of cells.G-202 is currently being evaluated in a Phase I safety and tolerability clinical trial at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, the University of Wisconsin Carbone Cancer Center, and the Cancer Therapy and Research Center at the University of Texas Health Science Center at San Antonio treating solid tumor cancer patients who have failed on other therapies.The company's second drug, G-115, targets an enzyme, PSA, that is secreted by normal prostate epithelial cells and prostate cancer cells.".
- GenSpera wikiPageExternalLink www.genspera.com.
- GenSpera wikiPageID "31257653".
- GenSpera wikiPageRevisionID "509635285".
- GenSpera hasPhotoCollection GenSpera.
- GenSpera subject Category:Biotechnology_companies_of_the_United_States.
- GenSpera subject Category:Companies_based_in_San_Antonio,_Texas.
- GenSpera subject Category:Companies_established_in_2003.
- GenSpera type Abstraction100002137.
- GenSpera type BiotechnologyCompaniesOfTheUnitedStates.
- GenSpera type CompaniesBasedInSanAntonio,Texas.
- GenSpera type CompaniesEstablishedIn2003.
- GenSpera type Company108058098.
- GenSpera type Group100031264.
- GenSpera type Institution108053576.
- GenSpera type Organization108008335.
- GenSpera type SocialGroup107950920.
- GenSpera type YagoLegalActor.
- GenSpera type YagoLegalActorGeo.
- GenSpera type YagoPermanentlyLocatedEntity.
- GenSpera comment "GenSpera, Inc. (OTC:BB GNSZ) is a development-stage oncology company based in San Antonio, Texas.".
- GenSpera label "GenSpera".
- GenSpera sameAs m.0gjdj_s.
- GenSpera sameAs Q5530845.
- GenSpera sameAs Q5530845.
- GenSpera sameAs GenSpera.
- GenSpera wasDerivedFrom GenSpera?oldid=509635285.
- GenSpera homepage www.genspera.com.
- GenSpera isPrimaryTopicOf GenSpera.